Michelle Iniguez, APRN
Family · Greenville, TXNPI 1578103859
Payments from drug & device makers
Across 210 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$974
- GSK$752
- Boehringer Ingelheim$418
- Sanofi$308
- Regeneron Healthcare Solutions, Inc.$255
- Mylan Specialty L.p.$230
- plus $1K from 18 others
What the payments were for
- Travel & lodging$281%
- Food & beverage$3,88797%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $974 |
| GSK | 49 | $752 |
| Boehringer Ingelheim | 20 | $418 |
| Sanofi | 13 | $308 |
| Regeneron Healthcare Solutions, Inc. | 11 | $255 |
| Mylan Specialty L.p. | 13 | $230 |
| Insmed, Inc. | 7 | $125 |
| Inspire Medical Systems, Inc. | 3 | $113 |
| Novartis | 6 | $108 |
| Grifols USA, LLC | 5 | $105 |
| Baxter Healthcare | 4 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Amgen | 5 | $79 |
| Viatris Specialty LLC | 3 | $73 |
| Harmony Biosciences LLC | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Electromed, Inc. | 5 | $39 |
| Johnson & Johnson | 2 | $31 |
| Tactile Systems Technology Inc | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Inogen, Inc. | 2 | $21 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$4,003 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 265 | $203,723 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 195 | $164,233 |
| Spiriva RespimatTiotropium Bromide | 43 | $31,589 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $12,822 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $11,791 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $11,695 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $11,359 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $10,808 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 343 | $10,453 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,655 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $7,597 |
| Arnuity ElliptaFluticasone Furoate | 21 | $4,265 |
| Roflumilast | 50 | $3,603 |
| Epinephrine | 16 | $3,070 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $752 | $242,282368 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $974 | $177,055238 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $418 | $51,60372 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $3,07016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Greenville
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.